Exogenous Galactosylceramide as Potential Treatment for CLN3 Disease.
El-Sitt S, Soueid J, Maalouf K, Makhoul N, Al Ali J, Makoukji J, Asser B, Daou D, Harati H, Boustany RM.
El-Sitt S, et al. Among authors: boustany rm.
Ann Neurol. 2019 Nov;86(5):729-742. doi: 10.1002/ana.25573. Epub 2019 Aug 28.
Ann Neurol. 2019.
PMID: 31393621